GLOBAL MORPHO PHARMA Belgique: what changed
GLOBAL MORPHO PHARMA Belgique
Largest movements
- Cash -€24
down €24 (-6.2%), from €396 to €372
mainly Net result for the year (-€1,691)
- Profit (loss) carried forward -€1,691
down €1,691 (-14.8%), from -€11,405 to -€13,096
- Other debts +€1,493
up €1,493 (+14.3%), from €10,414 to €11,907
- Trade debts +€166
up €166 (+44.9%), from €371 to €537
- Accrued charges and deferred income +€7
up €7 (+45.1%), from €16 to €23
- Financial charges -€301
down €301 (-31.1%), from €968 to €667
- Depreciation -€234
no longer reported in 2025 (was €234)
- Gross operating margin -€166
down €166 (-44.9%), from -€371 to -€537
- Purchases and services +€166
up €166 (+44.9%), from €371 to €537
- Other operating charges +€15
up €15 (+3.2%), from €472 to €487
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €396 | €372 | -€24 | -6.2% |
| Formation expenses | 20 | €0 | €0 | = | |
| Current assets | 29/58 | €396 | €372 | -€24 | -6.2% |
| Cash at bank and in hand | 54/58 | €396 | €372 | -€24 | -6.2% |
| Total equity and liabilities | 10/49 | €396 | €372 | -€24 | -6.2% |
| Equity | 10/15 | -€10,405 | -€12,096 | -€1,691 | -16.3% |
| Contributions | 10/11 | €1,000 | €1,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€11,405 | -€13,096 | -€1,691 | -14.8% |
| Amounts payable | 17/49 | €10,801 | €12,467 | +€1,667 | +15.4% |
| Amounts payable within one year | 42/48 | €10,785 | €12,444 | +€1,659 | +15.4% |
| Trade debts | 44 | €371 | €537 | +€166 | +44.9% |
| Suppliers | 440/4 | €371 | €537 | +€166 | +44.9% |
| Other amounts payable | 47/48 | €10,414 | €11,907 | +€1,493 | +14.3% |
| Accrued charges and deferred income | 492/3 | €16 | €23 | +€7 | +45.1% |
| Goods, raw materials, services and sundry goods | 60/61 | €371 | €537 | +€166 | +44.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €234 | - | -€234 | |
| Other operating charges | 640/8 | €472 | €487 | +€15 | +3.2% |
| Gross operating margin | 9900 | -€371 | -€537 | -€166 | -44.9% |
| Operating profit (loss) | 9901 | -€1,077 | -€1,024 | +€53 | +4.9% |
| Financial charges | 65/66B | €968 | €667 | -€301 | -31.1% |
| Recurring financial charges | 65 | €968 | €667 | -€301 | -31.1% |
| Profit (loss) for the period before taxes | 9903 | -€2,045 | -€1,691 | +€354 | +17.3% |
| Profit (loss) for the period | 9904 | -€2,045 | -€1,691 | +€354 | +17.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€2,045 | -€1,691 | +€354 | +17.3% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 2 November 2026 via checked.be.